ES2711075T3 - Compuestos para su uso en el tratamiento de trastornos cognitivos - Google Patents
Compuestos para su uso en el tratamiento de trastornos cognitivos Download PDFInfo
- Publication number
- ES2711075T3 ES2711075T3 ES12151551T ES12151551T ES2711075T3 ES 2711075 T3 ES2711075 T3 ES 2711075T3 ES 12151551 T ES12151551 T ES 12151551T ES 12151551 T ES12151551 T ES 12151551T ES 2711075 T3 ES2711075 T3 ES 2711075T3
- Authority
- ES
- Spain
- Prior art keywords
- carbons
- alkyl
- hydroxy
- independently selected
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- APMMBNUHWBPACY-ABLWVSNPSA-N NCCC(Cc1ccncc1)C(N(CC1)C[C@H]1F)=O Chemical compound NCCC(Cc1ccncc1)C(N(CC1)C[C@H]1F)=O APMMBNUHWBPACY-ABLWVSNPSA-N 0.000 description 1
- QYCSAKLRBWPHLA-WDSKDSINSA-N N[C@@H]([C@H](c1ccc[o]1)O)C(N)=O Chemical compound N[C@@H]([C@H](c1ccc[o]1)O)C(N)=O QYCSAKLRBWPHLA-WDSKDSINSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89319607P | 2007-03-06 | 2007-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2711075T3 true ES2711075T3 (es) | 2019-04-30 |
Family
ID=39535350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08731362T Active ES2383384T3 (es) | 2007-03-06 | 2008-03-04 | Un derivado de amidas de ácidos 3-heteroaril-3-hidroxi-2-aminopropiónicos específico para su uso en el tratamiento de ciertos trastornos cognitivos |
| ES12151551T Active ES2711075T3 (es) | 2007-03-06 | 2008-03-04 | Compuestos para su uso en el tratamiento de trastornos cognitivos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08731362T Active ES2383384T3 (es) | 2007-03-06 | 2008-03-04 | Un derivado de amidas de ácidos 3-heteroaril-3-hidroxi-2-aminopropiónicos específico para su uso en el tratamiento de ciertos trastornos cognitivos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8623891B2 (de) |
| EP (2) | EP2131837B1 (de) |
| JP (1) | JP2010520299A (de) |
| AU (3) | AU2008222890C1 (de) |
| BR (1) | BRPI0808353B8 (de) |
| CA (1) | CA2680324A1 (de) |
| DK (1) | DK2481407T3 (de) |
| ES (2) | ES2383384T3 (de) |
| HK (1) | HK1139855A1 (de) |
| PT (1) | PT2481407T (de) |
| TR (1) | TR201818771T4 (de) |
| WO (1) | WO2008109610A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0607304A2 (pt) * | 2005-01-26 | 2009-08-25 | Allergan Inc | compostos tendo atividade analgésica e/ou imunoestimulante |
| RU2491931C2 (ru) * | 2007-07-17 | 2013-09-10 | Аллерган, Инк. | Способы лечения тревоги |
| EP2453890B1 (de) * | 2009-07-17 | 2020-05-27 | Allergan, Inc. | Zusammensetzungen mit einem cholinesterasehemmer zur behandlung von kognitiven beeinträchtigungen |
| WO2011034915A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating disorders of gastrointestinal motility |
| CA2774355A1 (en) | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating spasticity |
| ES2440068T3 (es) | 2009-09-16 | 2014-01-27 | Allergan, Inc. | Compuestos para su uso en el tratamiento de trastornos convulsivos |
| EP3336079A1 (de) * | 2013-08-15 | 2018-06-20 | Allergan, Inc. | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(l)-(+)-tartratsalz, dessen verfahren zur herstellung und verwendung |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62114946A (ja) | 1985-11-13 | 1987-05-26 | Banyu Pharmaceut Co Ltd | フエニルセリンアミド誘導体およびそれを有効成分とする中枢神経系用剤 |
| WO1997010817A1 (en) * | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| NO965193L (no) * | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| GB9909064D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| SE9904197D0 (sv) | 1999-11-22 | 1999-11-22 | Amersham Pharm Biotech Ab | A method for anion exchange adsorption on matrices carrying mixed mode ligands |
| ES2395463T3 (es) * | 2001-07-16 | 2013-02-15 | Genzyme Corporation | Un inhibidor de N-acilesfingosina glucosiltransferasa |
| AU2002348261A1 (en) * | 2001-11-26 | 2003-06-10 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
| US20050101674A1 (en) * | 2003-11-12 | 2005-05-12 | Maurer Barry J. | PPMP as a ceramide catabolism inhibitor for cancer treatment |
| US20060081273A1 (en) * | 2004-10-20 | 2006-04-20 | Mcdermott Wayne T | Dense fluid compositions and processes using same for article treatment and residue removal |
| BRPI0607304A2 (pt) | 2005-01-26 | 2009-08-25 | Allergan Inc | compostos tendo atividade analgésica e/ou imunoestimulante |
| WO2008011485A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain |
| WO2008011483A2 (en) | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
-
2008
- 2008-03-04 WO PCT/US2008/055812 patent/WO2008109610A1/en active Application Filing
- 2008-03-04 AU AU2008222890A patent/AU2008222890C1/en active Active
- 2008-03-04 ES ES08731362T patent/ES2383384T3/es active Active
- 2008-03-04 TR TR2018/18771T patent/TR201818771T4/tr unknown
- 2008-03-04 ES ES12151551T patent/ES2711075T3/es active Active
- 2008-03-04 EP EP08731362A patent/EP2131837B1/de active Active
- 2008-03-04 US US12/530,124 patent/US8623891B2/en active Active
- 2008-03-04 BR BRPI0808353A patent/BRPI0808353B8/pt active IP Right Grant
- 2008-03-04 EP EP12151551.4A patent/EP2481407B1/de active Active
- 2008-03-04 PT PT12151551T patent/PT2481407T/pt unknown
- 2008-03-04 DK DK12151551.4T patent/DK2481407T3/en active
- 2008-03-04 JP JP2009552838A patent/JP2010520299A/ja active Pending
- 2008-03-04 CA CA002680324A patent/CA2680324A1/en not_active Abandoned
-
2010
- 2010-06-15 HK HK10105998.9A patent/HK1139855A1/xx not_active IP Right Cessation
-
2016
- 2016-06-24 AU AU2016204334A patent/AU2016204334B2/en active Active
-
2018
- 2018-06-15 AU AU2018204290A patent/AU2018204290B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0808353B1 (pt) | 2020-03-31 |
| US8623891B2 (en) | 2014-01-07 |
| PT2481407T (pt) | 2018-12-28 |
| ES2383384T3 (es) | 2012-06-20 |
| AU2008222890C1 (en) | 2016-09-08 |
| AU2018204290B2 (en) | 2020-05-21 |
| WO2008109610A1 (en) | 2008-09-12 |
| EP2481407B1 (de) | 2018-09-26 |
| US20100093793A1 (en) | 2010-04-15 |
| JP2010520299A (ja) | 2010-06-10 |
| BRPI0808353A2 (pt) | 2014-07-29 |
| AU2008222890A1 (en) | 2008-09-12 |
| AU2016204334B2 (en) | 2018-03-15 |
| HK1139855A1 (en) | 2010-09-30 |
| TR201818771T4 (tr) | 2019-01-21 |
| AU2008222890B2 (en) | 2016-03-31 |
| AU2016204334A1 (en) | 2016-07-14 |
| CA2680324A1 (en) | 2008-09-12 |
| EP2481407A1 (de) | 2012-08-01 |
| AU2018204290A1 (en) | 2018-07-05 |
| EP2131837A1 (de) | 2009-12-16 |
| DK2481407T3 (en) | 2019-01-07 |
| BRPI0808353B8 (pt) | 2021-05-25 |
| EP2131837B1 (de) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2711075T3 (es) | Compuestos para su uso en el tratamiento de trastornos cognitivos | |
| AR053011A1 (es) | Compuestos de heteroarilo como inhibidores del receptor p2y1, composiciones farmaceuticas que los contienen y su uso en la manufactura de un medicamento para el tratamiento de un trastorno tromboembolico | |
| GT200600496A (es) | Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea. | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| RU2003121236A (ru) | Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием | |
| IS6459A (is) | Arýl sambrædd azapólýsýklísk efnasambönd | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| NO20055631L (no) | Doseringsform inneholdende pantoprazol som aktiv ingrediens | |
| AR051686A1 (es) | Derivados de piridotienopirimidina; composiciones farmaceuticas que los contienen y su empleo en la fabricacion de un medicamento para el tratamiento de enfermedaes mediadas por inhibicion de pde4. | |
| CY1110450T1 (el) | Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσων | |
| AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
| AR043485A1 (es) | Derivados del 8'-piridinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona y 8´-pirimidinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona substituidos | |
| CL2022000889A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| NO20030155L (no) | Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav | |
| RU2018130994A (ru) | Новое соединение бисфосфоновой кислоты | |
| US9303021B2 (en) | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | |
| AR035613A1 (es) | Compuesto derivado de 2-piperidilimidazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento | |
| CA2468910C (en) | Use of 4-oxobutanoic acid derivatives in the treatment of inflammation | |
| ES2809298T3 (es) | Composiciones que comprenden un inhibidor de colinesterasa para tratar trastornos cognitivos | |
| EA201370026A1 (ru) | Способ, соединение, фармацевтическая композиция и лекарственное средство для восстановления утраченной памяти в норме и патологии | |
| EA201992005A1 (ru) | Арильные, гетероарильные и гетероциклические фармацевтические соединения для лечения медицинских нарушений | |
| RU2003125937A (ru) | 1,3-диоксо -2,3-дигидро- 1h-пирроло[3,4-c]хинолины (варианты), фармацевтические композиции (варианты), способ их получения (варианты) и способы лечения (варианты) | |
| RU2008152824A (ru) | Производные пиридинона и пиридазинона в качестве ингибиторов поли(adp-рибоза) полимеразы(parp) | |
| AR060473A1 (es) | Acidos 4-oxo-1, 4-dihidroquinolina como moduladores alostericos positivos del receptor m1, una composicion farmaceutica que los comprende y el uso de estos en la elaboracion de un medicamento para el tratamiento de la enfermedad de alzheimer, trastornos del dolor y del sueno. |